Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: A Brazilian perspective

Journal of Medical Economics

Volumn 11, Issue 3, 2008, Pages 383-396

  Stefani, Stephen Doral ^a,c   Saggia, Mario Giorgio ^b   dos Santos, Eduardo Augustus Vicino ^b  

^a Mãe de Deus Hospital   (Brazil)

^b Roche Brazil   (Brazil)

^c NONE   (Brazil)

Author keywords

Advanced NSCLC; Cost minimisation analysis; Docetaxel; Erlotinib; Pemetrexed

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; FOLIC ACID; IFOSFAMIDE; NAVELBINE; PEMETREXED; PLACEBO; PLATINUM COMPLEX;

ANOREXIA; ARTICLE; BRAZIL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST MINIMIZATION ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HEALTH CARE PRACTICE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDICAL CARE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PATIENT CARE; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SOCIAL SUPPORT; STOMATITIS;

ANTINEOPLASTIC AGENTS; BRAZIL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; COST CONTROL; DISEASE-FREE SURVIVAL; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; SENSITIVITY AND SPECIFICITY; TAXOIDS;

EID: 55049136500     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802208186     Document Type: Article

References (33)

1. Estimativa 2008. Incidência de Câncer no Brasil. Rio de Janeiro: INCA: Instituto National de Câncer. Available from: http://www.inca.gov.br/estimativa/2008/versaofinal.pdf [accessed 9 May 2008].
2. Algrand E, Menezes AM, Achuttil AC. Lung cancer in Brazil. Seminars in Oncology 2001; 28: 143-52.
3. Cancer Research UK. March 2007. Lung Cancer Factsheet. Available at: http://publications.cancerresearchuk.org/WebRoot/crukstoredb/CRUK_PDFs/ CSFSLUNG.pdf [accessed 10 March 2008].
4. Hotta K, Matsuo K, Ueoka H et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Annals of Oncology 2004; 15: 1782-1789.
5. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 2002; 346: 92-98.
6. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology 2000; 18: 2095-2103.
7. Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183-194.
8. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology 2004; 22: 1589-1597.
9. Moyer JD, Barbacci EG, Iwata KK et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Research 1997; 57: 4838-4848.
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine 2005; 353: 123-132.
11. Ramalingam S, Sandler AB. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. Oncologist 2006; 11: 655-665.
12. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of Life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. Journal of Clinical Oncology 2006; 24: 3831-3837.
13. Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-621.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 2.2008, 4 Feb 2008. Available from: http://www.nccn.org/professionals/physician_gls/PDF/ nscl.pdf [accessed 7 Mar 2008].
15. Fossella FV, De Vore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. Journal of Clinical Oncology 2000; 18: 2354-2362.
16. Guia Farmacêutico Brasíndice 632. Ano 42, 5 Mar 2007 [in Portuguese].
17. Classificação Brasileira Hierarquizada de Procedimentos M6dicos (CBHPM). 2004, Brasília. AMB (Associação Médica Brasileira) [in Portuguese].
18. Gobis O. Revista Simpro Vol Agosto/Setembro Ano 8 no. 45 ed. São Paulo, SP: Simpro Publicações e Teleprocessamento Ltda 2006 [in Portuguese].
19. Cohen MH, Johnson JR, Wang YC et al. FDA drug approval summary: pemetrexed for injection (Alimta®) for the treatment of non-small cell lung cancer. Oncologist 2005; 10: 363-368.
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer 2006. www.nccn.org [superseded by 2008 version].
21. Cuidados paliativos oncólogicos - Controle de sintomas. Revista brasileira de Cancerologia 2002; 48: 191-211 [in Portuguese].
22. BC Cancer Agency Guidelines March 2007. Available from: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Lung/ 6ManagementPolides/641NonSmallCellLungCancer/default.htm [accessed 26 March 2008].
23. Jun HX, Zhixiang S, Chun W et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. International Journal of Antimicrobial Agents 2005; 26(Suppl. 2): 128-132.
24. Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases 2002; 34: 730-751.
25. Holmes J, Dunlop D, Hemmett L, et al. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004; 22: 581-589.
26. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Critical Reviews in Oncology/Hematology 2004; 50: 129-146.
27. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007; 12: 478-483.
28. Ramsey SD, Clarke L Kamath et al. Evaluation of erlotinib in advanced non-small cell lung cancer: budget impact to a US health insurance plan. Journal of Managed Care Pharmacy 2006; 12: 472-478.
29. Lewis G, Morlotti L, Creeden J et al. Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC) in the UK. Value in Health 2006; 9: A203-A204 (Abstract CN4).
30. Pompen M, Novak A, Postmus P et al. Pharmacoeconomic (PE) analysis of the treatment of non-small-cell lung cancer (NSCLC) in The Netherlands demonstrates that erlotinib dominates docetaxel and is cost-effective over best supportive care (BSC) without need for patient stratification. Value in Health 2006; 9: A203 (Abstract CN3).
31. Orlewska E, Szcesna A, Gyldmark M et al. Cost effectiveness of erlotinib in the treatment of advanced non small cell lung cancer (NSCLC) in Poland. Value in Health 2006; 9: A279 (Abstract PCN12).
32. Rubio Terres C, Álvarez Sanz C. Pharmacoeconomic analysis of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small cell lung cancer who have failed previous chemotherapy regimens. Value in Health 2006; 9: A283-A284 (Abstract PCN26).
33. Kotowa W, Gatzemeier U, Pirk O et al. A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. Journal of Medical Economics 2007; 10: 255-271.